Insilico and Tenacia expand AI CNS pact to $94.75 million
CURRENT BRIEF VERSION: Insilico Medicine and Tenacia Biotechnology said on March 26, 2026, that they’re expanding their central nervous system drug discovery collaboration, adding a second AI-enabled program with potential deal value of up to $94.75 million. The partners said the original collaboration, launched in March 2025, focused on small-molecule inhibitors designed to cross the blood-brain barrier, and that the work has progressed enough to justify broadening the effort. Under the new agreement, Insilico will use its Pharma.AI platform with Tenacia’s neuroscience expertise and proprietary data to advance another candidate for difficult neurological diseases through the preclinical candidate stage. (prnewswire.com)
Why it matters: For veterinary professionals, this isn’t an animal health deal, but it’s another signal that AI-led discovery is moving from proof-of-concept into repeat business, especially in hard-to-treat CNS disease where blood-brain barrier penetration is a major challenge. Insilico has also been pushing its platform across multiple therapeutic areas and has said Pharma.AI’s reach extends into veterinary medicine. That broader momentum was reinforced this week by a separate Eli Lilly collaboration that could be worth up to $2.75 billion, includes $115 million upfront to Insilico, and gives Lilly exclusive global rights to develop, manufacture, and commercialize certain preclinical oral candidates plus work with Insilico on multiple Lilly-selected targets using Pharma.AI. Taken together, these partnerships are worth watching as indicators of how quickly AI tools may reshape early-stage drug discovery workflows, partner models, and expectations around speed in both human and animal health R&D. (prnewswire.com; PharmaShots)
What to watch: Watch for disclosure of the target, preclinical candidate timing, and whether Insilico converts more CNS partnerships into development-stage programs after its recent run of larger AI drug discovery deals, including the multi-program Lilly alliance. (prnewswire.com; PharmaShots)